Spoken Alpha
SUPN
SUPERNUS PHARMACEUTICALS, INC.
Overview
SUPERNUS PHARMACEUTICALS, INC is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $2.41B market cap.
Most recent reported earnings: Q3 FY2026 (Nov 2, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-08-30.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-0512 Q&A exchanges
- Q4 FY2025Earnings2026-02-2515 Q&A exchanges
- Q3 FY2025Earnings2025-11-0513 Q&A exchanges
- Q2 FY2025Earnings2025-08-058 Q&A exchanges
- Q1 FY2025Earnings2025-05-067 Q&A exchanges
- Q4 FY2024Earnings2025-02-2518 Q&A exchanges
- Q3 FY2024Earnings2024-11-049 Q&A exchanges
- Q2 FY2024Earnings2024-08-0613 Q&A exchanges
- Q1 FY2024Earnings2024-05-0810 Q&A exchanges
- Q4 FY2023Earnings2024-02-2714 Q&A exchanges
- Q3 FY2023Earnings2023-11-085 Q&A exchanges
- Q2 FY2023Earnings2023-08-0810 Q&A exchanges
- Q1 FY2023Earnings2023-05-0910 Q&A exchanges
- Q4 FY2022Earnings2023-02-287 Q&A exchanges
- Q3 FY2022Earnings2022-11-087 Q&A exchanges
- Q2 FY2022Earnings2022-08-073 Q&A exchanges
- Q1 FY2022Earnings2022-05-093 Q&A exchanges
- Q4 FY2021Earnings2022-02-2811 Q&A exchanges
- Q3 FY2021Earnings2021-11-0310 Q&A exchanges
- Q2 FY2021Earnings2021-08-043 Q&A exchanges
- Q1 FY2021Earnings2021-05-1017 Q&A exchanges
History
Earnings history
- Q3 FY20262026-11-02EPS— vs $0.66—Rev— vs ——EODHD
- Q2 FY20262026-08-02EPS$0.39 vs $0.30+30.0%Rev$219.1M vs ——EODHD
- Q1 FY20262026-05-04EPS$0.21 vs $0.28-25.0%Rev$207.7M vs ——EODHD
- Q4 FY20252026-03-02EPS$0.88 vs $0.41+100.0%Rev$211.6M vs ——EODHD
- Q3 FY20252025-11-03EPS$0.61 vs $0.82-25.6%Rev$192.1M vs ——EODHD
- Q2 FY20252025-08-04EPS$0.91 vs $0.47+93.6%Rev$165.5M vs ——EODHD
- Q1 FY20252025-05-05EPS$0.44 vs $0.37+18.9%Rev$149.8M vs ——EODHD
- Q4 FY20242025-02-24EPS$0.55 vs $0.52+5.4%Rev$174.2M vs ——EODHD
- Q3 FY20242024-11-03EPS$1.10 vs $0.44+100.0%Rev$175.7M vs ——EODHD
- Q2 FY20242024-08-05EPS$0.67 vs $0.39+71.8%Rev$168.3M vs ——EODHD
- Q1 FY20242024-05-07EPS$0.24 vs $0.38-36.8%Rev$143.6M vs ——EODHD
- Q4 FY20232024-02-26EPS$0.89 vs $0.55+61.8%Rev$164.3M vs ——EODHD
- Q3 FY20232023-11-07EPS$0.24 vs $0.08+100.0%Rev$153.9M vs ——EODHD
- Q2 FY20232023-08-07EPS$0.49 vs $0.21+100.0%Rev$135.6M vs ——EODHD
- Q1 FY20232023-05-08EPS$0.68 vs $0.31+100.0%Rev$153.8M vs ——EODHD
- Q4 FY20222023-02-27EPS$0.43 vs $0.68-36.8%Rev$167.3M vs ——EODHD
- Q3 FY20222022-11-07EPS$0.52 vs $0.46+13.0%Rev$177.4M vs ——EODHD
- Q2 FY20222022-08-03EPS$0.14 vs $0.29-51.7%Rev$170.1M vs ——EODHD
- Q1 FY20222022-05-08EPS$0.43 vs $0.45-4.4%Rev$152.5M vs ——EODHD
- Q4 FY20212022-02-27EPS$0.04 vs $0.24-83.3%Rev$159.1M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-02 | — | $0.66 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-02 | $0.39 | $0.30 | +30.0% | $219.1M | — | — | EODHD |
| Q1 FY2026 | 2026-05-04 | $0.21 | $0.28 | -25.0% | $207.7M | — | — | EODHD |
| Q4 FY2025 | 2026-03-02 | $0.88 | $0.41 | +100.0% | $211.6M | — | — | EODHD |
| Q3 FY2025 | 2025-11-03 | $0.61 | $0.82 | -25.6% | $192.1M | — | — | EODHD |
| Q2 FY2025 | 2025-08-04 | $0.91 | $0.47 | +93.6% | $165.5M | — | — | EODHD |
| Q1 FY2025 | 2025-05-05 | $0.44 | $0.37 | +18.9% | $149.8M | — | — | EODHD |
| Q4 FY2024 | 2025-02-24 | $0.55 | $0.52 | +5.4% | $174.2M | — | — | EODHD |
| Q3 FY2024 | 2024-11-03 | $1.10 | $0.44 | +100.0% | $175.7M | — | — | EODHD |
| Q2 FY2024 | 2024-08-05 | $0.67 | $0.39 | +71.8% | $168.3M | — | — | EODHD |
| Q1 FY2024 | 2024-05-07 | $0.24 | $0.38 | -36.8% | $143.6M | — | — | EODHD |
| Q4 FY2023 | 2024-02-26 | $0.89 | $0.55 | +61.8% | $164.3M | — | — | EODHD |
| Q3 FY2023 | 2023-11-07 | $0.24 | $0.08 | +100.0% | $153.9M | — | — | EODHD |
| Q2 FY2023 | 2023-08-07 | $0.49 | $0.21 | +100.0% | $135.6M | — | — | EODHD |
| Q1 FY2023 | 2023-05-08 | $0.68 | $0.31 | +100.0% | $153.8M | — | — | EODHD |
| Q4 FY2022 | 2023-02-27 | $0.43 | $0.68 | -36.8% | $167.3M | — | — | EODHD |
| Q3 FY2022 | 2022-11-07 | $0.52 | $0.46 | +13.0% | $177.4M | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $0.14 | $0.29 | -51.7% | $170.1M | — | — | EODHD |
| Q1 FY2022 | 2022-05-08 | $0.43 | $0.45 | -4.4% | $152.5M | — | — | EODHD |
| Q4 FY2021 | 2022-02-27 | $0.04 | $0.24 | -83.3% | $159.1M | — | — | EODHD |
Source: EODHD. SUPN reported actuals as published; sparse fields render as —.
Top executives
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
- Jack A KhattarCEO11 yr 6 mo20 callsCurrent
- Timothy C DecCFO5 yr 1 mo19 callsCurrent
- Jonathan RubinSVP, Chief Medical Officer5 yr 8 mono recorded callsCurrent
- Padmanabh P BhattSr. VP of IP, CSO11 yr 8 mono recorded callsCurrent
- William Todd HorichSVP, Commercial Operations6 mono recorded callsCurrent
- Frank MottolaSVP, Chief Tech. Ops. Officer1 yrno recorded callsCurrent
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for SUPN.
$ curl https://api.spokenalpha.com/v1/companies/SUPNFAQ
Frequently asked about SUPN
Where can I find SUPERNUS PHARMACEUTICALS, INC.'s (SUPN) earnings call transcripts?
Spoken Alpha indexes SUPN's earnings call transcripts at https://spokenalpha.com/companies/SUPN. Each call links to attributed speakers and parsed analyst Q&A. SUPERNUS PHARMACEUTICALS, INC.'s own investor relations page is at https://ir.supernus.com/.
When was SUPERNUS PHARMACEUTICALS, INC.'s most recent earnings call?
SUPERNUS PHARMACEUTICALS, INC. (SUPN) held its most recent earnings call on 2026-05-05, covering fiscal Q1 2026.
What sector is SUPN in?
SUPERNUS PHARMACEUTICALS, INC. (SUPN) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).